Evaluation of Atacand® (candesartan) in daily medical practice

Study identifier:NIS-CSI-ATA-2005/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 12-week open-label non-interventional evaluation of Atacand® (candesartan) efficacy, tolerability, compliance and treatment satisfaction in patients with arterial hypertension

Medical condition

hypertension

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

750

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Mar 2006

Primary Completion Date: -

Study Completion Date: 01 Jun 2007

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

CSR-NIS-CSI-ATA-2005-1.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Slovenia Clinical Study Information

+38615135623

[email protected]

Investigators

Principal Investigator

Rok Accetto

University Medical Center Ljubljana